Bicara Therapeutics BCAX Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance.
The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount?
- Bicara Therapeutics (BCAX) reported effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount of $7.87M in Q4 2025.
- What does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount mean?
- This metric represents the dollar amount of adjustments made to the valuation allowance for deferred tax assets. An increase in the allowance suggests management has become more conservative regarding the future realization of tax benefits, often due to sustained operating losses. It is a key indicator of the company's tax-related financial health and future earnings potential.